Induction of phenotypic changes in HER2-postive breast cancer cells in vivo and in vitro.
Authors: Frank-Kamenetskii A, Mook J, Reeves M, Boulanger CA, Meyer TJ, Ragle L, Jordan HC, Smith GH, Booth BW Abstract The influence of breast cancer cells on normal cells of the microenvironment, such as fibroblasts and macrophages, has been heavily studied but the influence of normal epithelial cells on breast cancer cells has not. Here using in vivo and in vitro models we demonstrate the impact epithelial cells and the mammary microenvironment can exert on breast cancer cells. Under specific conditions, signals that originate in epithelial cells can induce phenotypic and genotypic changes in cancer cells. We ha...
Source: Oncotarget - August 13, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Cell morphology impact on the set-up of electroporation protocols for in-suspension and adhered breast cancer cells.
Authors: Vera-Tizatl CE, Talamás-Rohana P, Vera-Hernández A, Leija-Salas L, Rodríguez-Cuevas SA, Chávez-Munguía B, Vera-Tizatl AL Abstract In order to establish cancer-type-specific electroporation protocols for breast cancer, electroporation was performed in vitro in two modalities: in-suspension and adhered cells. Electroporation of cell suspensions was carried out through commercial electroporation cuvettes whereas a novel electrode for electroporation of adhered cells was designed and manufactured aimed to preserve cell structure, to provide a closer model to an in vivo scenar...
Source: Electromagnetic Biology and Medicine - August 13, 2020 Category: Physics Tags: Electromagn Biol Med Source Type: research

Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States.
CONCLUSION: The increasing use of chemotherapy as patients progressed to second and later lines and the substantial direct/indirect economic burden underscore an unmet need. The high number of 1L regimens highlights significant heterogeneity and a lack of consensus related to the management of HR+/HER2- MBC in routine practice. PMID: 32755262 [PubMed - as supplied by publisher] (Source: Expert Review of Pharmacoeconomics and Outcomes Research)
Source: Expert Review of Pharmacoeconomics and Outcomes Research - August 13, 2020 Category: Health Management Tags: Expert Rev Pharmacoecon Outcomes Res Source Type: research

HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer
Publication date: Available online 10 August 2020Source: Pathology - Research and PracticeAuthor(s): Jing Zhao, Uma Krishnamurti, Chao Zhang, Jane Meisel, Zhimin Wei, Aili Suo, Ritu Aneja, Zaibo Li, Xiaoxian Li (Source: Pathology Research and Practice)
Source: Pathology Research and Practice - August 13, 2020 Category: Pathology Source Type: research

Labeling a TCO-functionalized single domain antibody fragment with 18F via inverse electron demand Diels Alder cycloaddition using a fluoronicotinyl moiety-bearing tetrazine derivative.
Abstract Single domain antibody fragments (sdAbs) exhibit a rapid tumor uptake and fast blood clearance amenable for labeling with 18F (t½ = 110 min) but suffer from high kidney accumulation. Previously, we developed a method for 18F-labeling of sdAbs via trans-cyclooctene (TCO)-tetrazine (Tz) inverse electron demand Diel's Alder cycloaddition reaction (IEDDAR) that incorporated a renal brush border enzyme (RBBE)-cleavable linker. Although>15 fold reduction in kidney activity levels was achieved, tumor uptake was compromised. Here we investigate whether replacing the [18F]AlF-NOTA moiety with [18F]...
Source: Bioorganic and Medicinal Chemistry - August 13, 2020 Category: Chemistry Authors: Zhou Z, Zalutsky MR, Vaidyanathan G Tags: Bioorg Med Chem Source Type: research

Hsa-miR-155-5p Up-Regulation in Breast Cancer and Its Relevance for Treatment With Poly[ADP-Ribose] Polymerase 1 (PARP-1) Inhibitors
miR-155-5p is a well-known oncogenic microRNA, showing frequent overexpression in human malignancies, including breast cancer. Here, we show that high miR-155-5p levels are associated with unfavorable prognostic factors in two independent breast cancer cohorts (CSS cohort, n = 283; and TCGA-BRCA dataset, n = 1,095). Consistently, miR-155-5p results as differentially expressed in the breast cancer subgroups identified by the surrogate molecular classification in the CSS cohort and the PAM50 classifier in TCGA-BRCA dataset, with the TNBC and HER2-amplified tumors carrying the highest levels. Since the analysis of TCGA-BC dat...
Source: Frontiers in Oncology - August 12, 2020 Category: Cancer & Oncology Source Type: research

Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2  cm or smaller (T1N0) breast cancer.
CONCLUSION: Patients with both HER2+ and high expression level of TOP2A protein predicts poor prognosis in T1N0 breast cancer patients. Patients with double positive for TOP2A protein and HER2 may benefit from anthracycline-based regimens. PMID: 32780321 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - August 11, 2020 Category: Cancer & Oncology Authors: Zhong W, Yang Y, Zhang A, Lin W, Liang G, Ling Y, Zhong J, Yong J, Liu Z, Tian Z, Lin Q, Luo Q, Li Y, Gong C Tags: Breast Cancer Source Type: research

Docetaxel plus S-1 versus cisplatin plus S-1 in unresectable gastric cancer without measurable lesions: a randomized phase II trial (HERBIS-3)
AbstractBackgroundCisplatin plus S-1 (CS) is the standard first-line chemotherapy for advanced gastric cancer (AGC) in Japan. A previous phase III trial showed that docetaxel plus S-1 (DS) was effective for AGC without measurable lesions, but no studies have compared these two regimens.MethodsEligible patients had unresectable or recurrent HER2-negative AGC without measurable lesions. Patients were randomized to DS (docetaxel 40  mg/m2 on day 1, S-1 80 –120 mg on days 1–14, every 3 weeks) or CS (cisplatin 60 mg/m2 on day 8, S-1 80 –120 mg on days 1–21, every 5 weeks). T...
Source: Gastric Cancer - August 10, 2020 Category: Gastroenterology Source Type: research

Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer.
CONCLUSION: Therapy-related cardiotoxicity is an uncommon complication of anti-HER2 therapy in the real world setting. Cardiac toxicity resolved in the majority of affected patients, and further anti-HER2 therapy was administered without recurrence of cardiac issues. Our data suggests anti-HER2 therapy can be safely given in routine care, even in patients with risk factors for toxicity. PMID: 32779390 [PubMed - as supplied by publisher] (Source: Clinical Genitourinary Cancer)
Source: Clinical Genitourinary Cancer - August 10, 2020 Category: Cancer & Oncology Authors: Conduit C, de Boer RH, Lok S, Gibbs P, Malik L, Loh Z, Yeo B, Greenberg S, Devitt B, Lombard J, Nottage M, Collins I, Torres J, Nolan M, Nott L Tags: Asia Pac J Clin Oncol Source Type: research

Study of Ki-67 index in the molecular subtypes of breast cancer: Inter-observer variability and automated scoring
Conclusion: The inter-observer correlation and the correlation with the automated scoring system of the Ki-67 index was good. 29.1% was the mean Ki-67 index in the ER/PR positive group and this value was within the acceptable range as per St Galen's recommendation. (Source: Indian Journal of Cancer)
Source: Indian Journal of Cancer - August 10, 2020 Category: Cancer & Oncology Authors: Divya Meermira Meenakshi Swain Swarnalata Gowrishankar Source Type: research

Intraoperative Radiation Therapy Versus Whole Breast Radiation for Early-Stage Breast Cancer Treatment in Rural Appalachia.
We report our experience with IORT in patients undergoing BCS versus whole breast radiation therapy (WBRT). METHODS: Retrospective review of patients undergoing BCS with IORT versus WBRT (2012-2017). Inclusion: low grade, T1-2N0M0, estrogen receptor/progesterone receptor positive, and Her2-negative infiltrating ductal carcinomas. IORT was delivered as a single fraction of radiation (20 Gy) intraoperatively. Outcomes were compared using Fisher's test for discrete variables or Wilcoxon signed-rank test for continuous variables. Kaplan-Meier method was used to estimate disease-free survival (DFS). RESULTS: Fifty-one...
Source: The American Surgeon - August 10, 2020 Category: Surgery Authors: Abdelsattar JM, McClain K, Afridi FG, Wen S, Cai Y, Musgrove KA, Bailey K, Shaikh PM, Jacobson GM, Marsh W, Lupinacci K, Cowher MS, Jenkins HH Tags: Am Surg Source Type: research

Prevalence of Histological Characteristics of Breast Cancer in Rwanda in Relation to Age and Tumor Stages
AbstractBreast cancer is a complex disease, and it is the most common cause of morbidity and mortality among women worldwide. In Sub-Saharan Africa, the clinical characteristics and tumor profiles of breast cancer are still unknown. In the present study we aimed to determine breast tumor profiles of the Rwandan patients in relation to age and tumor stages. We compare our findings to related results from other sub-Saharan Africa studies. Data on age at diagnosis, tumor stage, and hormonal profiles of 138 patients diagnosed between January 2015 and December 2018 were retrospectively retrieved from electronic medical records ...
Source: Hormones and Cancer - August 9, 2020 Category: Cancer & Oncology Source Type: research

Cardiovascular risk after adjuvant trastuzumab in early breast cancer: an Italian population-based cohort study.
DISCUSSION: In our large real-world investigation, T-associated cardiotoxicity was limited to the treatment period. The addition of T to adjuvant CT did not result in long-term worsening of CV events. IMPLICATION FOR PRACTICE: Adjuvant trastuzumab-based chemotherapy represents the backbone therapy in HER2 positive early breast cancer patients. Although well tolerated, cardiovascular events can manifest during or after therapy due to treatment-related toxicities. In our wide multicentre and unselected cohort, long-term symptomatic cardiotoxicity was low and limited to the treatment period. The findings suggest that dev...
Source: The Oncologist - August 8, 2020 Category: Cancer & Oncology Authors: Franchi M, Trama A, Merlo I, Minicozzi P, Tarantini L, Garau D, Kirchmayer U, Di Martino M, Romero M, De Carlo I, Scondotto S, Apolone G, Corrao G, Fabio Working Group Tags: Oncologist Source Type: research

Melatonin Administered before or after a Cytotoxic Drug Increases Mammary Cancer Stabilization Rates in HER2/Neu Mice
Conclusions: MT supplementation to cytotoxic drugs can improve antitumor response, especially if it is blunted because of an inappropriate time of administration.Chemotherapy (Source: Chemotherapy)
Source: Chemotherapy - August 7, 2020 Category: Cancer & Oncology Source Type: research

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring human epidermal growth factor receptor 2 amplification (JUPITER trial)
Discussion: The aim of this trial is to evaluate the safety and efficacy of combination therapy with trastuzumab and pertuzumab in patients with locally advanced or metastatic, solid cancers harboring HER2 amplification. Instead of focusing on 1 organ type, our trial design uses a basket study focusing on HER2 amplification, regardless of the site or origin of the cancer. The results of our study will advance clinical and scientific knowledge concerning the treatment of locally advanced, rare solid cancers harboring HER2 amplification, using the combination of trastuzumab and pertuzumab. Trial registration: This trial...
Source: Medicine - August 7, 2020 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research

Cancers, Vol. 12, Pages 2209: Therapeutic Potential of Chemically Modified miR-489 in Triple-Negative Breast Cancers
Ju Jun Chung Triple-negative breast cancers (TNBCs) lack ER, PR and her2 receptors that are targets of common breast cancer therapies with poor prognosis due to their high rates of metastasis and chemoresistance. Based on our previous studies that epigenetic silencing of a potential metastasis suppressor, arrestin domain-containing 3 (ARRDC3), is linked to the aggressive nature of TNBCs, we identified a sub-group of tumor suppressing miRNAs whose expressions were significantly up-regulated by ARRDC3 over-expression in TNBC cells. Among these tumor suppressing miRs, we found that miR-489 is most anti-proliferative in...
Source: Cancers - August 7, 2020 Category: Cancer & Oncology Authors: Young Hwa Soung Heesung Chung Cecilia Yan Andrew Fesler Hyungjin Kim Eok-Soo Oh Jingfang Ju Jun Chung Tags: Article Source Type: research

The Role of Biomarkers to Evaluate Cardiotoxicity
Opinion statementModerate-level evidence suggests that cardiac troponin and natriuretic peptides are useful for risk stratification and early identification of anthracycline cardiotoxicity; however, many of these studies used older chemotherapy regimens, and thus, the applicability to current anthracycline treatment regimens is uncertain. Further research is needed to determine optimal timing and thresholds for troponin and natriuretic peptides in anthracycline-treated patients and evaluate these and other promising biomarkers for anti-HER2 therapies, thoracic radiation, anti-VEGF therapy, and fluoropyrimidine therapy &nda...
Source: Current Treatment Options in Oncology - August 7, 2020 Category: Cancer & Oncology Source Type: research

The Evolving Landscape of HER2-Directed Breast Cancer Therapy
Opinion statementThe management of patients with HER2+ breast cancer has evolved significantly over the preceding decades. HER2 targeting strategies have advanced beyond focusing on the receptor alone to encompass a range of approaches. Current standard of care practices in these patients relies upon dual HER2 blockade with trastuzumab and pertuzumab in the adjuvant and metastatic settings. T-DM1 has proven particularly efficacious in patients with residual disease status post neoadjuvant therapy, with additional therapies approved in the subsequent lines to address recurrent and resistant disease. Advances continue to be ...
Source: Current Treatment Options in Oncology - August 7, 2020 Category: Cancer & Oncology Source Type: research

Clinicopathological and genomic features of breast mucinous carcinoma.
Abstract INTRODUCTION: Mucinous carcinoma (MC) of the breast is a special histological type of breast cancer. Clinicopathological characteristics and genomic features of MC is not fully understood. MATERIALS AND METHODS: 186,497 primary breast cancer patients from SEER database diagnosed with invasive ductal carcinoma (IDC) or MC were included. 801 primary IDC or MC patients from TCGA cohort were included for transcriptomic and genomic analysis. RESULTS: MC patients were older, had lower tumor grade and T and N stage, higher hormone receptor positive proportions and lower HER2 positive proportions than I...
Source: Breast - August 6, 2020 Category: Cancer & Oncology Authors: Lu K, Wang X, Zhang W, Ye H, Lao L, Zhou X, Yao S, Lv F Tags: Breast Source Type: research

Virus-Mimicking Nanoparticles for Targeted Near Infrared Fluorescence Imaging of Intraperitoneal Ovarian Tumors in Mice.
Abstract Ovarian cancer is the most lethal malignancy affecting the female reproductive system. Identification and removal of all ovarian intraperitoneal tumor deposits during the intraoperative surgery is important towards preventing cancer recurrence and ultimately improving patient survival. Herein, we investigate the effectiveness of virus mimicking nanoparticles, derived from genome-depleted plant-infecting brome mosaic virus, and doped with near infrared (NIR) brominated cyanine dye BrCy106-NHS, for targeted NIR fluorescence imaging of intraperitoneal ovarian tumors. We refer to these nanoparticles as optica...
Source: Annals of Biomedical Engineering - August 6, 2020 Category: Biomedical Engineering Authors: Vankayala R, Bahena E, Guerrero Y, Singh SP, Ravoori MK, Kundra V, Anvari B Tags: Ann Biomed Eng Source Type: research

Clinical, histopathological and immunohistochemical features of brain metastases originating in colorectal cancer: a series of 27 consecutive cases.
CONCLUSIONS: BMs originating in CRC represent a rare pathology and have particular clinical and IHC features that could vary from one series to another series. In a few cases, BMs may be diagnosed in the absence of a known CRC diagnosis and in these situations, the correct diagnosis is of interest. However, a panel of antibodies can help in establishing a correct diagnosis. Our study was among the first to analyze the HER2∕neu expression pattern in BMs from CRC and we found a strong aberrant nuclear expression of this molecular marker on IHC investigation. Related to the data published so far in the literature, it is pos...
Source: Romanian Journal of Morphology and Embryology - August 5, 2020 Category: General Medicine Tags: Rom J Morphol Embryol Source Type: research

[Research Articles] Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype
Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to therapy, leading to relapse. Using patient-derived xenografts (PDXs), we observed that mCRC cells surviving EGFR inhibition exhibited gene expression patterns similar to those of a quiescent subpopulation of normal intestinal secretory precursors with Paneth cell characteristics. Compared with untreated tumors, these pseudodifferentiated tumor remnants had reduced expression of genes encoding EGFR-activatin...
Source: Science Translational Medicine - August 5, 2020 Category: Biomedical Science Authors: Lupo, B., Sassi, F., Pinnelli, M., Galimi, F., Zanella, E. R., Vurchio, V., Migliardi, G., Gagliardi, P. A., Puliafito, A., Manganaro, D., Luraghi, P., Kragh, M., Pedersen, M. W., Horak, I. D., Boccaccio, C., Medico, E., Primo, L., Nichol, D., Spiteri, I. Tags: Research Articles Source Type: research

Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling
Tissue-based testing for predictive biomarkers to guide selection of matched targeted therapy is standard-of-care in advanced non-small cell lung cancer (NSCLC)[1]. Genomic biomarkers for Food and Drug Administration (FDA)-approved therapies in NSCLC include EGFR activating mutations, EGFR T790  M, BRAF V600E, rearrangements in ALK or ROS1, and more recently pan-tumor approvals for NTRK1-3 rearrangements and high microsatellite instability (MSI-H). National Comprehensive Cancer Network (NCCN) NSCLC clinical practice guidelines additionally suggest testing for emerging biomarkers includin g RET rearrangement, MET exo...
Source: Lung Cancer - August 5, 2020 Category: Cancer & Oncology Authors: Russell Madison, Alexa B. Schrock, Emily Castellanos, Jeffrey P. Gregg, Jeremy Snider, Siraj M. Ali, Vincent A. Miller, Gaurav Singal, Brian M. Alexander, Jeffrey M. Venstrom, Jon H. Chung Tags: ORIGINAL RESEARCH ARTICLE Source Type: research

Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Abstract A series of O-substituted analogues of the B,C-ring truncated scaffold of deguelin were designed as C-terminal inhibitors of heat shock protein 90 (HSP90) and investigated as novel antiproliferative agents against HER2-positive breast cancer. Among the synthesized compounds, compound 80 exhibited significant inhibition in both trastuzumab-sensitive and trastuzumab-resistant breast cancer cells, whereas compound 80 did not show any cytotoxicity in normal cells. Compound 80 markedly downregulated the expression of the major client proteins of HSP90 in both cell types, indicating that the cytotoxicity of 80 ...
Source: Bioorganic and Medicinal Chemistry Letters - August 4, 2020 Category: Chemistry Authors: Nguyen CT, Ann J, Sahu R, Byun WS, Lee S, Nam G, Park HJ, Park S, Kim YJ, Kim JY, Seo JH, Lee J Tags: Bioorg Med Chem Lett Source Type: research

Recurrence/Regrowth in Grade I Meningioma: How to Predict?
The HLA-G and HLA-E molecules, Ki67, progesterone (PR), estrogen (ER) and androgen receptors (AR), p53, COX-2, and HER2 were studied to assess whether the biological behavior of grade I meningiomas is related to their expression. Tissue samples from 96 patients with grade I intracranial meningiomas were analyzed by immunohistochemistry on tissue microarray blocks (TMA) using antibodies specific for HLA-G, HLA-E, Ki67, PR, ER, AR, p53, COX-2, and HER2. Meningiomas were classified as small (≤2 cm, 1.0%), medium (>2 and ≤4 cm, 32.3%), and large (>4 cm, 66.7%). Tumor size was not related to recurrence/regrowth (p =...
Source: Frontiers in Oncology - August 4, 2020 Category: Cancer & Oncology Source Type: research

Catalog of Lung Cancer Gene Mutations Among Chinese Patients
Conclusion: We offer a detailed catalog of the distribution of lung cancer mutations. Showing how gender, smoking history, age, and pathological types are significantly related to the prevalence of lung cancer in China. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - August 4, 2020 Category: Cancer & Oncology Source Type: research

Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer
Gastric cancer remains third leading cause of global cancer mortality and is the fifth most common type of cancer in the United States. A select number of gastric cancers harbor alterations in EGFR and/or have amplification/overexpression in the HER2; 2–35 and 9–38%, respectively. The advent of next-generation sequencing of tissue and circulating tumor DNA has allowed for the massive expansion of targeted therapeutics to be employed in many settings. There have been a handful of trials using EGFR inhibitors with modest outcomes. Using novel strategies to target multiple co-mutations as well as identifying immun...
Source: Frontiers in Oncology - August 4, 2020 Category: Cancer & Oncology Source Type: research

Cost-Effectiveness of Tucatinib in Human Epidermal Growth Factor Receptor 2 –Positive Metastatic Breast Cancer From the US and Chinese Perspectives
Conclusion: In the United States and China, tucatinib combined with trastuzumab and capecitabine is not cost-effective for patients with HER-2 positive metastatic breast cancer. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - August 4, 2020 Category: Cancer & Oncology Source Type: research

Advanced lesions of synchronous bilateral mammary Paget ’s disease: a case report
ConclusionsIn a patient with suspicious chronic inflammation of the nipple and areolae, prompt biopsy should be performed to avoid a delayed diagnosis of any malignant breast lesion. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - August 4, 2020 Category: General Medicine Source Type: research

A New Multi-action Pt(IV) Conjugate with Oleate and Cinnamate Ligands Targets Human Epithelial Growth Factor Receptor HER2 in Aggressive Breast Cancer Cells.
Abstract HER2-positive breast cancer represents aggressive subtype typical of poor response to standard chemotherapy. To design an anticancer drug selective for HER2 expressing breast cancer, the new Pt(IV) prodrug with axial oleate and cinnamate ligands was synthesized. We demonstrate its superior antiproliferative activity in monolayer and 3D spheroid models; the antiproliferative efficiency increases gradually with increasing expression of HER2. The results also suggest that the released Pt(II) compound inhibits the proliferation of cancer cells by DNA-damage mediated mechanism. Simultaneously, the released ole...
Source: Angewandte Chemie - August 4, 2020 Category: Chemistry Authors: Kostrhunova H, Zajac J, Markova L, Brabec V, Kasparkova J Tags: Angew Chem Int Ed Engl Source Type: research

Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Conclusion: Immuno-PET using anti-CEA/anti-IMP288 bispecific antibody, followed by 68Ga-IMP288, is a potentially sensitive theranostic imaging method for HER2-negative, CEA-positive metastatic breast cancer patients and warrants further research. (Source: Journal of Nuclear Medicine)
Source: Journal of Nuclear Medicine - August 3, 2020 Category: Nuclear Medicine Authors: Rousseau, C., Goldenberg, D. M., Colombie, M., Sebille, J.-C., Meingan, P., Ferrer, L., Baumgartner, P., Cerato, E., Masson, D., Campone, M., Rauscher, A., Fleury, V., Labbe, C., Chauvet, A. F., Fresnel, J.-S., Toquet, C., Barbet, J., Sharkey, R. M., Camp Tags: Clinical Source Type: research

Biologic Drug Quality Assurance to Optimize HER2  + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3
AbstractSB3 is a biosimilar of trastuzumab that has been approved for use in the treatment of human epidermal growth factor 2-positive breast cancer and human epidermal growth factor 2-positive gastric cancer. Antibody-dependent cellular cytotoxicity is one of several critical quality attributes of trastuzumab. Data from the development of SB3 support the hypothesis of a relationship between antibody-dependent cellular cytotoxicity activity and clinical outcomes in terms of the response rate and long-term survival. Current analytic methods utilizing advanced technology allow the detection of small changes in other quality ...
Source: Targeted Oncology - August 3, 2020 Category: Cancer & Oncology Source Type: research

Systemic treatment options for advanced biliary tract carcinoma
AbstractAdvanced biliary  tract cancers (BTC) include a diverse collection of rare and heterogenous tumors with poor prognosis. The combination of gemcitabine and cisplatin is the established first-line therapy for advanced BTC. There are no accepted standard treatments in the second line setting, though there are sev eral ongoing clinical trials that implement chemotherapy as a therapeutic strategy. The understanding of the molecular landscape of BTC has offered hope of targeted therapies to the identified actionable genomic aberrations, such as FGFR2 gene fusions, mutations of IDH1/2, HER2, ...
Source: Journal of Gastroenterology - August 3, 2020 Category: Gastroenterology Source Type: research

Working together for the family: determination of HER oncogene co-amplifications in breast cancer.
In this study we designed a probemix to detect the amplification of the four HER oncogenes in a single reaction. In addition, we developed a protocol based on the combination of MLPA with ddPCR to detect the tumor proportion of co-amplified HERs. On 111 IDC, the HER2 MLPA results were validated by FISH (Adjusted r 2 = 0,91, p
Source: Oncotarget - August 2, 2020 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Surrogate Molecular Classification of Invasive Breast Carcinoma: A Comparison Between Core Needle Biopsy and Surgical Excision, With and Without Neoadjuvant Therapy
Surrogate molecular classification identifies different subtypes of invasive breast carcinoma on the basis of their immunohistochemical markers. The purpose of the study is to verify whether the immunohistochemical markers and surrogate molecular subtypes can be correctly assessed on the core needle biopsy (CNB) when compared with the corresponding surgical excision (SE), with or without neoadjuvant treatment (NAT). Cases with invasive carcinomas identified on both CNB and SE were retrospectively selected. With immunohistochemistry for estrogen receptors (ER), progesterone receptors (PgR), Ki67, human epidermal growth fact...
Source: Applied Immunohistochemistry and Molecular Morphology - August 1, 2020 Category: Chemistry Tags: Research Articles Source Type: research

Extramammary Paget Disease of the Scrotum: A Contemporary Clinicopathologic Analysis of 20 Cases in the United States
In conclusion, EMPD of the scrotum has an insidious onset and its nonspecific symptoms can be misdiagnosed as dermatitis or fungal infection. Although localized EMPD has a favorable prognosis, the invasive disease is rare and did not predict metastasis or progression. Margins are frequently positive requiring reexcision. Occasionally, cases can be positive for PSA leading to diagnostic pitfalls. (Source: Applied Immunohistochemistry and Molecular Morphology)
Source: Applied Immunohistochemistry and Molecular Morphology - August 1, 2020 Category: Chemistry Tags: Research Articles Source Type: research

Role of Melatonin in Breast Carcinoma: Correlation of Expression Patterns of Melatonin-1 Receptor With Estrogen, Progesterone, and HER2 Receptors
Breast carcinoma is a multifaceted-etiology malignancy. The presence of estrogen (ER), progesterone (PR), and HER2 (human epidermal growth factor receptor 2) receptors in breast carcinoma tissue has therapeutic implications. Recent studies indicate that pineal hormone melatonin by its receptor melatonin 1 (MT1) also influences the development and growth of breast cancer cells. The aim of this cross-sectional study was to elucidate the expression pattern of MT1 receptor in relation to estrogen, progesterone, and HER2 receptors in breast carcinoma. Two groups (receptor positive and triple negative) of breast carcinoma were t...
Source: Applied Immunohistochemistry and Molecular Morphology - August 1, 2020 Category: Chemistry Tags: Research Articles Source Type: research

High Ki-67 expression is a marker of poor survival in apocrine breast carcinoma.
Authors: Wysocka J, Adamczyk A, Kruczak A, Niemiec J, Sas-Korczyńska B Abstract Apocrine carcinoma is a very rare type of breast cancer, which represents 0.5-4% of all breast cancers. The aim of the study was to analyze biological and clinical features of apocrine carcinoma and their influence on patients survival. The studied group consists of 57 patients, who underwent treatment between 1987 and 2010. Expression of ER, PgR, HER2, AR, GCDFP-15, EGFR, CK 5/6, CK 8/18 and Ki-67 was assessed immunohistochemically on formalin-fixed paraffin-embedded tissue sections. Presen...
Source: Polish Journal of Pathology - August 1, 2020 Category: Pathology Tags: Pol J Pathol Source Type: research

Management of HER2-positive breast cancer during pregnancy: a case report and literature review.
CONCLUSIONS: When conception occurs inadvertently during assumption of tamoxifen or anti-HER2 agents, their effects on the fetus and on the course of pregnancy are not completely understood. Further studies are needed in this setting, highlighting the importance to share clinical experiences. PMID: 32729389 [PubMed - as supplied by publisher] (Source: Tumori)
Source: Tumori - August 1, 2020 Category: Cancer & Oncology Tags: Tumori Source Type: research

The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model.
CONCLUSION: The introduction of MGAs in the clinical evaluation of patients with luminal eBC with intermediate risk is economically sustainable and contributes towards preserving quality of life of eligible women. PMID: 32729378 [PubMed - as supplied by publisher] (Source: Tumori)
Source: Tumori - August 1, 2020 Category: Cancer & Oncology Tags: Tumori Source Type: research

Pyrotinib Sensitizes 5-Fluorouracil-resistant HER2+ Breast 4 Cancer Cells to 5-Fluorouracil.
In conclusion,our findings suggest that pyrotinib could restore sensitivity of 5-FU-resistant HER2+breast cancer cells to 5-FU through downregulating the expression levels of TS andABCG2. PMID: 32727638 [PubMed - as supplied by publisher] (Source: Oncology Research)
Source: Oncology Research - July 31, 2020 Category: Cancer & Oncology Tags: Oncol Res Source Type: research

HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib
HER2 mutations have emerged as oncogenic driver gene mutations in non-small cell lung cancer (NSCLC), which have not been described in detail like other driver gene mutations. Here, 295 patients with advanced lung adenocarcinoma were retrospectively screened for HER2 mutations using next-generation sequencing (NGS), and the positive cases were validated by Sanger sequencing. We identified five cases with HER2 exon 20 insertions, representing 1.7% of 295 lung adenocarcinomas. Among them, four different subtypes of HER2 exon 20 insertions were identified, including a rare subtype G778_S779insCPG never reported before with a ...
Source: Frontiers in Oncology - July 31, 2020 Category: Cancer & Oncology Source Type: research

The adaptor protein SHCA launches cancer invasion [Cell Biology]
Cancer cell invasion and metastasis rely on invadopodia, important extensions of the cytoskeleton that initiate degradation of the basement membrane that holds a cell in place. Transforming growth factor-β (TGF-β) is well-known to induce breast cancer migration and invasion, but the mechanism by which TGF-β signaling converts into cell motility is not completely understood. A study from Kiepas et al. revealed a new TGF-β–dependent role for Src homology/collagen adaptor protein (SHCA) in the initiation of dynamic adhesion complexes involved in the formation of invadopodia. These results highlight n...
Source: Journal of Biological Chemistry - July 31, 2020 Category: Chemistry Authors: Supriya Borah, Neil A. Bhowmick Tags: Editors ' Picks Highlights Source Type: research

Cancers, Vol. 12, Pages 2131: Natural Born Killers: NK Cells in Cancer Therapy
Hodge Cellular therapy has emerged as an attractive option for the treatment of cancer, and adoptive transfer of chimeric antigen receptor (CAR) expressing T cells has gained FDA approval in hematologic malignancy. However, limited efficacy was observed using CAR-T therapy in solid tumors. Natural killer (NK) cells are crucial for tumor surveillance and exhibit potent killing capacity of aberrant cells in an antigen-independent manner. Adoptive transfer of unmodified allogeneic or autologous NK cells has shown limited clinical benefit due to factors including low cell number, low cytotoxicity and failure to migrate to ...
Source: Cancers - July 31, 2020 Category: Cancer & Oncology Authors: S. Elizabeth Franks Benjamin Wolfson James W. Hodge Tags: Review Source Type: research

Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients
Background: The 21-gene recurrence score (RS) assay has been proven prognostic and predictive for hormone receptor-positive/HER2-negative, node-negative early breast cancer patients. However, whether primary 21-gene RS can predict prognosis in recurrent breast cancer patients remained unknown.Patients and Methods: Consecutive breast cancer patients operated in Comprehensive Breast Health Center, Shanghai Ruijin Hospital between January 2009 and December 2018 were retrospectively analyzed. Patients with available 21-gene RS result for the primary tumor and reporting disease recurrence during follow-up were included. Associa...
Source: Frontiers in Oncology - July 31, 2020 Category: Cancer & Oncology Source Type: research

Trastuzumab emtansine: a game changer in HER2-positive early breast cancer
Future Oncology, Ahead of Print. (Source: Future Oncology)
Source: Future Oncology - July 31, 2020 Category: Cancer & Oncology Authors: Max S  Mano Source Type: research

New Drugs for Breast Cancer
The kinase inhibitor tucatinib (Tukysa) has been approved to treat advanced unresectable or metastatic HER2-positive breast cancer. The drug is given orally in combination with trastuzumab (Herceptin) and capecitabine (Xeloda). It is not first-line therapy.Sacituzumab govitecan-hziy (Trodelvy) has been approved to treat triple-negative breast cancer that has metastasized. It is a targeted therapy monoclonal antibody given by IV infusion. The drug carries a boxed warning for risk of severe neutropenia and severe diarrhea. (Source: AJN)
Source: AJN - July 30, 2020 Category: Nursing Tags: Drug Watch Source Type: research

Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature
We described the case of a young patient with NF2 treated for long time with Bevacizumab. Here, we report the update of the previous case report. (Source: Anti-Cancer Drugs)
Source: Anti-Cancer Drugs - July 30, 2020 Category: Cancer & Oncology Tags: Case Reports Source Type: research

Status of 10 targeted genes of non ‐small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution
In this research, we investigated the frequency of common driving genes in 884 patients with non ‐small cell lung cancer and analyzed their association with clinicopathologic parameters in in eastern China. Most patients had at least one genetic alteration, and individual patients harbored synchronous mutation. Each gene alteration has unique clinicopathologic characteristics. BackgroundThe status of targeted genes and the association between targeted genes and clinicopathological features in Chinese lung cancer patients remains to be elucidated.MethodsThe status of 10 targeted genes was evaluated by next ‐generation s...
Source: Thoracic Cancer - July 30, 2020 Category: Cancer & Oncology Authors: Dan Li, Li Ding, Wenwen Ran, Yan Huang, Guangqi Li, Chengqin Wang, Yujing Xiao, Xiaonan Wang, Dongliang Lin, Xiaoming Xing Tags: ORIGINAL ARTICLE Source Type: research

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer.
CONCLUSIONS: Combining oncogenic driver targeted vaccines with selective ICB offers a rational paradigm for precision immunotherapy, which we are clinically evaluating in a phase II trial (NCT03632941). PMID: 32732224 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - July 30, 2020 Category: Cancer & Oncology Authors: Crosby EJ, Acharya CR, Haddad AF, Rabiola CA, Lei G, Wei JP, Yang XY, Wang T, Liu CX, Wagner KU, Muller WJ, Chodosh LA, Broadwater G, Hyslop T, Shepherd JH, Hollern DP, He X, Perou CM, Chai S, Ashby BK, Vincent BG, Snyder JC, Force J, Morse MA, Lyerly HK, Tags: Clin Cancer Res Source Type: research